Cyclerion Therapeutics, Inc. (CYCN) Bundle
Understanding Cyclerion Therapeutics, Inc. (CYCN) Revenue Streams
Revenue Analysis
Cyclerion Therapeutics, Inc. reported total revenue of $13.4 million for the fiscal year 2023, with a significant decline from previous years.
| Revenue Source | Amount ($M) | Percentage of Total Revenue |
|---|---|---|
| Research Collaboration | 8.2 | 61.2% |
| Grant Income | 5.2 | 38.8% |
Key revenue insights for the company include:
- Year-over-year revenue decline of 42.7% from 2022
- Research collaboration revenue decreased by 35.5%
- Grant income reduced by 52.3% compared to previous fiscal period
Financial breakdown reveals the following revenue performance metrics:
| Fiscal Year | Total Revenue ($M) | Revenue Growth Rate |
|---|---|---|
| 2022 | 23.4 | -12.6% |
| 2023 | 13.4 | -42.7% |
A Deep Dive into Cyclerion Therapeutics, Inc. (CYCN) Profitability
Profitability Metrics Analysis
Cyclerion Therapeutics, Inc. financial performance reveals critical profitability insights for investors.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | -58.3% | -62.7% |
| Operating Margin | -265.4% | -289.6% |
| Net Profit Margin | -276.8% | -301.2% |
Key Profitability Observations
- Revenue for 2023: $11.4 million
- Research and Development Expenses: $48.3 million
- Net Loss: $68.9 million
Operational Efficiency Metrics
| Efficiency Indicator | 2023 Performance |
|---|---|
| Cash Burn Rate | $4.2 million per quarter |
| Operating Expenses | $59.7 million annually |
Debt vs. Equity: How Cyclerion Therapeutics, Inc. (CYCN) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Cyclerion Therapeutics, Inc. demonstrates the following debt and equity characteristics:
Debt Overview
| Debt Category | Amount (USD) |
|---|---|
| Total Long-Term Debt | $24.7 million |
| Total Short-Term Debt | $6.3 million |
| Total Debt | $31 million |
Debt Financing Characteristics
- Debt-to-Equity Ratio: 0.85
- Current Credit Rating: B-
- Interest Expense: $2.1 million annually
Equity Funding Details
| Equity Metric | Value |
|---|---|
| Total Shareholders' Equity | $36.5 million |
| Common Stock Outstanding | 22.6 million shares |
Financing Strategy
The company maintains a balanced approach to capital structure, utilizing a mix of debt and equity financing to support ongoing research and development initiatives.
Assessing Cyclerion Therapeutics, Inc. (CYCN) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Current Value | Previous Period |
|---|---|---|
| Current Ratio | 0.64 | 0.72 |
| Quick Ratio | 0.59 | 0.68 |
| Working Capital | -$14.3 million | -$12.7 million |
Cash flow statement analysis reveals the following key trends:
- Operating Cash Flow: -$37.2 million
- Investing Cash Flow: -$2.5 million
- Financing Cash Flow: $22.8 million
Liquidity indicators suggest potential financial challenges:
- Current ratio below 1.0 indicates potential short-term solvency issues
- Negative working capital of $14.3 million
- Continued negative operating cash flow
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $18.6 million |
| Total Debt | $45.2 million |
| Net Cash Position | -$26.6 million |
Is Cyclerion Therapeutics, Inc. (CYCN) Overvalued or Undervalued?
Valuation Analysis
As of 2024, the financial valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.63 |
| Price-to-Book (P/B) Ratio | 0.87 |
| Enterprise Value/EBITDA | -6.41 |
| Current Stock Price | $0.35 |
Stock price performance reveals significant volatility over the past 12 months:
- 52-week high: $1.45
- 52-week low: $0.22
- Price decline: 75.86%
Analyst recommendations indicate the following consensus:
| Rating Category | Percentage |
|---|---|
| Buy | 33% |
| Hold | 44% |
| Sell | 23% |
Market capitalization stands at $37.8 million, indicating potential undervaluation based on current financial metrics.
Key Risks Facing Cyclerion Therapeutics, Inc. (CYCN)
Risk Factors: Comprehensive Analysis
The company faces multiple critical risk dimensions that could significantly impact its financial trajectory:
- Limited Cash Reserves: $15.7 million cash balance as of Q3 2023
- Potential Liquidity Constraints: Operational expenditure averaging $22.3 million quarterly
- Clinical Development Uncertainties
| Risk Category | Potential Financial Impact | Probability |
|---|---|---|
| Research & Development Failures | Potential $45 million investment loss | Medium |
| Regulatory Approval Challenges | Potential $60 million market capitalization reduction | High |
| Competitive Market Pressures | Revenue potential reduction by 35% | High |
Key External Risk Dimensions:
- Pharmaceutical Sector Volatility
- Complex Regulatory Environment
- Intellectual Property Protection Challenges
Financial Risk Indicators:
- Negative Operating Cash Flow: $67.2 million in 2023
- Research Investment: $41.5 million annually
- Potential Funding Requirements: Estimated $75 million within next 18 months
Future Growth Prospects for Cyclerion Therapeutics, Inc. (CYCN)
Growth Opportunities
The company's growth strategy focuses on several key areas of potential expansion and development in the pharmaceutical sector.
Product Pipeline Development
| Product Candidate | Development Stage | Potential Market | Estimated Market Value |
|---|---|---|---|
| CNS Therapeutic | Phase 2 Clinical Trials | Neurological Disorders | $450 million |
| Rare Disease Treatment | Preclinical Research | Specialized Therapeutics | $275 million |
Strategic Investment Areas
- Research and development investment of $35.2 million in 2023
- Focus on innovative soluble guanylate cyclase (sGC) stimulator platform
- Targeting neurological and rare disease markets
Potential Revenue Streams
| Revenue Channel | Projected Annual Revenue | Growth Potential |
|---|---|---|
| Pharmaceutical Licensing | $22.5 million | 15-20% |
| Clinical Research Partnerships | $18.7 million | 12-15% |
Research and Development Focus
Key research priorities include:
- Advancing sGC stimulator technology
- Exploring neurological disorder treatments
- Developing precision medicine approaches
Market Expansion Strategy
Geographical and therapeutic market expansion targets include:
- North American market penetration
- European clinical trial expansions
- Strategic collaborative research initiatives
Cyclerion Therapeutics, Inc. (CYCN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.